Approximately 5% of the world-wide population is affected by autoimmune diseases.
Overall, autoimmune diseases are still difficult to treat, impose a high burden on patients …

Autoimmune blistering diseases such as bullous pemphigoid (BP) and pemphigus vulgaris
(PV) are complex, multifactorial, and polygenic diseases, whose exact pathogenesis is …

Autoimmune bullous dermatoses (AIBD) are a heterogeneous group of about a dozen
diseases characterized clinically by erosions and blisters and immunopathologically by …

The patient in this manuscript has given written informed consent to the publication of his
case details. Twelve cases developed after Pfizer vaccine and six after Moderna vaccine …

HLA class II molecules are key factors determining susceptibility to autoimmune disorders,
and their role in immune-mediated skin conditions such as psoriasis has been extensively …

Introduction Bullous pemphigoid (BP) is the most common autoimmune blistering disease. It
predominately afflicts the elderly and is significantly associated with increased mortality. The …

Introduction Treatment options for autoimmune bullous diseases (AIBD) are currently limited
to corticosteroids and traditional immunomodulants and immunosuppressants that are …

Bullous pemphigoid (BP) is an autoimmune blistering disease that mainly affects the elderly.
The human leukocyte antigen (HLA) system is believed to be one of the genetic factors …

Bullous pemphigoid (BP) is the most common autoimmune blistering disorder. Several
factors, including an antidiabetic (dipeptidyl peptidase-4 inhibitor [DPP-4i]), have been …

Background and Objectives. Numerous genome‐wide association studies have highlighted
that chronic lymphocytic leukemia (CLL) is a lymphoproliferative disorder with an important …